Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial
Open Access
- 3 December 2014
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 15 (1), 1-8
- https://doi.org/10.1186/1745-6215-15-474
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Transarterial chemoembolization with/without cryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinomaExperimental and Therapeutic Medicine, 2012
- The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional PerspectiveThe Oncologist, 2010
- Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survivalJournal of Hepatology, 2010
- Radioembolization for Hepatocellular Carcinoma Using Yttrium-90 Microspheres: A Comprehensive Report of Long-term OutcomesGastroenterology, 2010
- 778 SURVIVAL OF UNRESECTABLE HEPATOCELLULAR CARCINOMA: A META-ANALYSIS OF THE CONTROL ARMS OF 28 RANDOMIZED TRIALSJournal of Hepatology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosisJournal of Hepatology, 2007
- Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantationJournal of Surgical Oncology, 2006
- Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18European Journal of Cancer, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000